Debrisoquine polymorphism novel CYP2D6 gene bam HI restriction fragment length polymorphism in the ngawbé guaymí indian of panama

Daniel D. Petersen, Ah Ng T. Kong, Lucia F. Jorge, Daniel W. Nebert, Tomas D. Arias

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Markedly decreased cytochrome P450-mediated metabolism of debrisoquine, sparteine, and more than two dozen additional commonly prescribed drugs is an autosomal recessive trait that has been associated with several RFLP patterns involving the CYP2D6 gene. In Caucasians there are at least six variant alleles known to be correlated with the ‘poor metabolizer’ (PM) phenotype. We examined debrisoquine and sparteine metabolism and CYP2D6 RFLP patterns in 22 Ngawbe Guaymi Indians of Panama. We studied a two-generation family, a three-generation family, and three other unrelated PM individuals. Digestion of all 22 DNA samples with Xba I or Hind III did not produce the same varying CYP2D6 RFLP patterns as those commonly seen in at least two-thirds of all Northern European Caucasians and Chinese so far screened. In contrast, we found a single heretofore undescribed Bam HI polymorphism that was correlated with the PM phenotype among all Ngawbe Guaymi individuals examined. It is possible that this novel RFLP might represent a recent founder effect that has occurred in this unadmixed Amerindian tribe within the past 20 000-30 000 years.

Original languageAmerican English
Pages (from-to)136-142
Number of pages7
JournalPharmacogenetics
Volume1
Issue number3
DOIs
StatePublished - Dec 1991
Externally publishedYes

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Debrisoquine polymorphism novel CYP2D6 gene bam HI restriction fragment length polymorphism in the ngawbé guaymí indian of panama'. Together they form a unique fingerprint.

Cite this